Detalles de la búsqueda
1.
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
Br J Cancer
; 115(10): 1206-1214, 2016 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27736842
2.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Br J Cancer
; 115(8): 974-982, 2016 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27623234
3.
Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.
Biomol Biomed
; 23(5): 760-771, 2023 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37021836
4.
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.
Cancers (Basel)
; 14(5)2022 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267477
5.
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Clin Colorectal Cancer
; 17(3): 206-214, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29703606
Resultados
1 -
5
de 5
1
Próxima >
>>